Detail akcie CareDx online

Business Summary: CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, CareDx Inc revenues increased 10% to $271.4M. Net loss decreased 46% to $17.2M. Revenues reflect Rest of the world segment increase of 26% to $5M. Lower net loss reflects Services Medical Laboratories segment loss decrease of 99% to $246K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.61 to -$0.32.